Total third quarter core pharmaceutical revenue reached $2 billion.
Growth portfolio revenue rose 49% year over year in Q3.
Biogen repaid $400 million of term loans during the third quarter.
On its third-quarter 2026 earnings call, held on Oct. 28, 2026, Biogen (NASDAQ:BIIB) announced that it's on track to deliver full-year top-line growth, driven by core commercial expansion and the performance of acquired products. A stabilizing core portfolio alongside faster growth from newly acquired therapies gives the business a durable revenue foundation. That stability allows the company to execute on its pipeline of late-stage drug candidates without relying entirely on unproven clinical trials.
Three things management said stand out.
The acquisition of Apellis Pharmaceuticals added SYFOVRE, a therapy for geographic atrophy, an eye condition, and Empaveli, a drug for rare kidney and blood disorders, creating a $1 billion annual run-rate asset base. Cost synergies arrived ahead of schedule, so operating dilution is now negligible.
The first point I would make on that is given the Appellis acquisition, we now think that the company can grow even without the pipeline.
-- Christopher A. Viehbacher, President and Chief Executive Officer
Conversion to high-dose SPINRAZA, a treatment for spinal muscular atrophy (SMA), a genetic neuromuscular disorder, exceeded internal targets during the quarter. Patients and prescribers are moving quickly to the elevated dose, providing strong momentum for the rare disease franchise.
At the end of Q3, 70% of the 12 mg patients now have a start form submitted, which is very high. And we know that 50% have now been dosed the product.
-- Alisha Alaimo, President North America
Late-stage clinical trials are approaching key milestones, beginning with phase 3 studies for litifilumab in systemic lupus erythematosus (SLE), an autoimmune disease affecting multiple organs. Upcoming readouts across immunology and kidney disease offer multiple opportunities to expand the commercial footprint.
Beyond that, we expect to continue our multiyear cycle of important registrational data flow through the end of the decade.
-- Priya Singhal, Head of Development
Core pharmaceutical revenue expanded 18% year over year, proving that commercial execution and product integration are driving top-line acceleration across key markets.
In closing, Q3 26 was another strong quarter and a continuation of the momentum we have seen this year.
-- Robin C. Kramer, Chief Financial Officer
Durable legacy treatments, expanding commercial reach in rare diseases, and accelerated cost synergies give the business distinct structural advantages. Management is watching upcoming phase 3 trial readouts, reimbursement expansion for subcutaneous treatments, and disciplined term loan debt repayment. These operational levers align to support multiyear growth while maintaining balance sheet flexibility.
And I think you know, if we have reasonable success with the pipeline, you know, again, we have to wait and see the results, but there is a good potential that the company can just grow now for the foreseeable future.
-- Christopher A. Viehbacher, President and Chief Executive Officer
Before you buy stock in Biogen, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Biogen wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $959,410!*
Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 17, 2026.
The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.